对细胞因子风暴综合征的抗干扰素-γ 治疗
Edward M Behrens1, Fabrizio de Benedetti2
1Division of Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Advances in experimental medicine and biology
|August 8, 2024
概括
过度的干扰素- (IFN-γ) 生产驱动血细胞性淋巴细胞瘤 (HLH). 向IFN-γ显示出治疗这种疾病的前景,初步的人类研究表明安全性和有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 病理生理学 病理生理学
背景情况:
- 干扰素- (IFN-γ) 在先天性和适应性免疫以及宿主防御机制中起着至关重要的作用.
- 过度的IFN-γ产生与超细胞因子症的发病和血细胞淋巴细胞细胞瘤 (HLH) 的临床表现有很大关系.
- HLH包括原发性遗传形式和继发性遗传形式,两者都与免疫失调有关.
研究的目的:
- 审查IFN-γ在免疫反应和宿主防御中的多方面的作用.
- 总结了初级和二级HLH动物模型的发现,重点是治疗策略.
- 讨论IFN-γ通路生物标志物的临床实用性以及人类HLH中IFN-γ中和疗法的初始结果.
主要方法:
- 对IFN-γ功能和HLH现有证据的文献综述.
- 从研究HLH病原和治疗的动物模型中分析数据.
- 对IFN-γ通路生物标志物和治疗干预措施的临床数据的审查.
主要成果:
- IFN-γ是免疫反应的关键调解者,其失调对HLH有显著的贡献.
- 动物模型突出了针对IFN-γ用于HLH治疗的潜力.
- IFN-γ通路激活的生物标志物与HLH有关,IFN-γ中和的初始人体试验显示了令人鼓舞的安全性和有效性.
结论:
- IFN-γ是HLH病变发生的核心驱动因素.
- 准IFN-γ通路是HLH的一种有前途的治疗策略.
- 对IFN-γ中和的进一步临床研究对于HLH管理是有必要的.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
109
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
109
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Tumor Immunotherapy
497
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
497
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K


